Wr-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment

International Journal of Pancreatology

Volumn 29, Issue 1, 2001, Pages 19-23

  Makhluf, Huda A ^a   Mueller, Stefan M ^a   Mizuno, Shuichi ^a   Glowacki, Julie ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gemcitabine; Pancreatic cancer; Radiation damage; Radioprotector; WR 2721 (amifostine)

Indexed keywords

AMIFOSTINE; GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; TOXICITY; WHOLE BODY RADIATION;

AMIFOSTINE; ANIMALS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; JEJUNUM; MICE; MICE, INBRED C3H; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; WHOLE-BODY IRRADIATION;

EID: 0034822246     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/IJGC:29:1:19     Document Type: Article

References (20)

1. Enhancement of tumor radioresponse in vivo by gemcitabine
2. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials
3. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery
4. Adjuvant and neoadjuvant chemoradiation therapy for primary colorectal cancer
5. Chemoradiotherapy: Radiosensitizing nucleoside analogues
6. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer
7. Maximizing therapeutic gain with gemcitabine and fractionated radiation
8. Radiosensitization produced in vivo by once vs twice weekly 2′, 2′-difluoro-2′-deoxycytidine (gemcitabine)
9. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
10. Phase I trial of twice weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
11. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity
12. Radioprotective effects of amifostine
13. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721
14. Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721)
15. Amifostine and combined-modality therapeutic approaches
16. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients
17. Biology based combined modality radiotherapy: Workshop report
18. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation
19. Gemcitabine: Progress in the treatment of pancreatic cancer
20. Current approaches and future strategies for pancreatic carcinoma